Navigation Links
AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers

FAIRFAX, Va., Dec. 3 /PRNewswire-USNewswire/ -- Allergy & Asthma Network Mothers of Asthmatics (AANMA) announced today that a new Web-based video geared to help people successfully manage the transition from CFC albuterol inhalers to HFA inhalers is now available at its Web site, Smart Moves to an HFA Inhaler uses technology that allows viewers to ask questions in everyday language and immediately receive a response with relevant, highly focused answers. Users can obtain valuable information about why inhalers are changing, the differences between newer and older inhalers, cost concerns and how to use new HFA inhalers.

"We created this video to help patients and their families learn more about this federal mandate, as a significant number of patients are still not aware of how to safely go about making this change," said Nancy Sander, president and founder of AANMA. "At the end of the year, inhalers are changing. These changes are mandatory, and there are important decisions to make about treatment options that require thoughtful consideration of the patient's medical history and current respiratory health status."

In less than 30 days, life-saving albuterol inhalers used by nearly 40 million patients with respiratory disorders will no longer be sold. After December 31, 2008, it will no longer be permissible to manufacture or sell albuterol inhalers in the United States that contain chlorofluorocarbon (CFC) propellants, because they destroy the Earth's ozone layer. These inhalers have been replaced with four distinct non-CFC propelled alternatives, which contain hydrofluoroalkane (HFA) propellant.

While the transition has been forthcoming for some time, data from IMS Health show that an estimated 14 million CFC prescriptions have yet to be transitioned to HFA MDIs.(1) The absence of a medically responsible transition protocol leaves patients unknowingly exposed to health risks beyond their control.

Patients with asthma, COPD and other respiratory conditions use albuterol at the first sign of symptoms, before exercise and when experiencing breathing exacerbations. Because there are significant differences between CFC and HFA inhalers, patients and medical professionals need to have the opportunity to make the switch in a medically responsible way.

The Web module is hosted by former CNN Medical correspondent Rea Blakey, and supported by an educational grant from Sepracor.

For more information about the MDI transition, please visit AANMA's MDI Transition Web page at Patients seeking information can also call AANMA's Patient Support Center at 800-315-8056.


Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit

(1) IMS NPA, August 22, 2008

SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
2. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
3. United American Healthcare Corporation Announces Stock Repurchase Program
4. eOn Communications Announces GSA Contract
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment
7. Elsevier announces the 2008 supplement of Reproductive Health Matters
8. Pascal Metrics Announces Patient Safety Culture Services Offering
9. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology: